There are very few experimental studies that have characterized the effects of cannabinoids in this sample. Lindeman and Malamud [132] administered unassayed doses of hashish to a group of schizophrenic patients, “neurotics” and normals. “Normal” individuals developed paranoid delusions, impulsivity, and marked perceptual changes, and schizophrenic patients experienced an exacerbation of symptoms [132].
